Veeva’s launch acceleration strategy focuses on the new treatment awareness and adoption journeys of the most relevant healthcare professionals (HCPs) and key opinion leaders (KOLs).
Launching a new drug has always been fraught with risks and today three in four launches fail to meet or outperform forecasts.1 Early medical engagement improves the likelihood of launch success: Veeva Pulse data shows that pre-launch field medical education can lead to a 1.5x increase in treatment adoption. Similarly, biopharmas with higher investments in pre launch scientific activity experience 40% faster treatment adoption.
To overcome these challenges and capitalize on unique insights within Veeva Data Cloud, Veeva Business Consulting provides launch teams with accelerators that can be deployed across the launch lifecycle.
Together, these capabilities help teams go earlier, deeper, and faster during launch. Simple changes can unlock transformative change, enabling more consistent execution across markets and driving up to 25% difference in post-launch treatment adoption.
Learn how Veeva Business Consulting can help your organization achieve launch excellence.
1 Strategy&, ‘Bridging Pharma’s $200 million commercial gap’, 2023
2 U.S.-based analysis of migraine products using data from Veeva Link, Veeva OpenData, Veeva Compass, and Veeva Pulse, March 2019-June 2023
3 US based analysis of oncology products using data from Veeva Link, Veeva OpenData, Veeva Compass and Veeva Pulse, October 2020 – April 2024